brepocitinib · Lisraya

Small molecule

Also known as PF-06700841

Approvedregulatory verdict

Evidence outlook

Approved: Dermatomyositis (label: adults), Idiopathic Inflammatory Myopathies

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Latest reported trial: VALOR (NCT05437263) · Phase 3 · met primary endpoint · grade pending

Also in development:Non-Infectious Uveitis · Phase 3Cutaneous Sarcoidosis · Phase 2/3Lichen Planopilaris · Phase 2/3

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (2)
Idiopathic Inflammatory Myopathies
Other / comorbidity
Phase 2/3 (2)
Cutaneous Sarcoidosis
Lichen Planopilaris
Phase 2 (13)
Idiopathic Inflammatory Myopathies
NCT06433999 · Priovant Therapeutics, Inc.
2024-08-28 – 2025-02-28 · Dermatomyositis, Dermatomyositis, Adult Type
What this study did
Psoriasis
NCT03850483 · Pfizer
2019-04-08 – 2021-04-20 · Psoriasis
What this study did
Other / comorbidity
NCT05523765 · Priovant Therapeutics, Inc.
2022-11-14 – 2024-07-30 · Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Non-infectious Pan Uveitis
What this study did
NCT03395184 · Pfizer
2018-02-02 – 2023-10-19 · Crohn's Disease
What this study did
NCT03845517 · Pfizer
2019-04-18 – 2023-10-05 · Systemic Lupus Erythematosus
What this study did
NCT05076006 · Emma Guttman
2021-05-19 – 2023-09-30 · Cicatricial Alopecia
What this study did
NCT04092452 · Pfizer
2019-12-02 – 2022-01-10 · Acne Inversa
What this study did
NCT02958865 · Pfizer
2017-02-03 – 2021-05-10 · Ulcerative Colitis
What this study did
NCT03715829 · Pfizer
2018-11-26 – 2021-02-05 · Active Non-segmental Vitiligo
What this study did
NCT03963401 · Pfizer
2019-06-13 – 2021-01-15 · Psoriatic Arthritis
What this study did
NCT02974868 · Pfizer
2016-12-15 – 2019-05-15 · Alopecia Areata
What this study did
Phase 1 (9)
Psoriasis
Other / comorbidity
NCT04260464 · Pfizer
2020-07-03 – 2022-05-04 · Healthy Volunteer, Renal Impairment
What this study did
NCT04580797 · Pfizer
2020-10-02 – 2021-01-11 · Healthy Participants
What this study did
NCT04267250 · Pfizer
2020-08-24 – 2020-11-06 · Healthy Female Volunteers
What this study did
NCT04090047 · Pfizer
2019-09-24 – 2019-12-19 · Heathy Participants
What this study did
NCT03765554 · Pfizer
2019-01-07 – 2019-04-03 · Healthy Participants
What this study did
NCT03770039 · Pfizer
2018-12-10 – 2019-02-21 · Healthy Male Subjects
What this study did
NCT03656952 · Pfizer
2018-09-05 – 2019-02-06 · Healthy
What this study did
NCT03236493 · Pfizer
2017-08-16 – 2017-10-12 · Healthy
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 1 (1)
Other / comorbidity

Competitive landscape

4 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Dermatomyositis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Brepocitinib (Lisraya): this drugApprovedSmall moleculeTYK2/JAK1not yet gradedNo reviewed efficacy summary in this indication
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
PF-06823859Phase 3Monoclonal antibodyInterferon beta (IFN-beta)not yet gradedNo reviewed efficacy summary in this indication
BHV-8000
Phase 2/3(overall)
Small moleculeTYK2/JAK1
not yet graded(overall)
No reviewed efficacy summary in this indication
TDM-180935
Phase 2(overall)
Small moleculeTYK2/JAK1
Partial signal(overall)
No reviewed efficacy summary in this indication
Descartes-08Phase 1/2Cell therapyBCMA (B-cell maturation antigen)not yet gradedNo reviewed efficacy summary in this indication
CadefrecitinibDiscontinuedSmall moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Lisraya (brepocitinib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (2)
December 2028 (2)
Phase 2/3Lichen PlanopilarisRecruiting
Est. primary completion 2028-12-31 · NCT07532603 · CT.gov ↗
What to watch
Phase 2/3Cutaneous SarcoidosisRecruiting
Est. primary completion 2028-12-31 · NCT06978725 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

21 October 2026Topline resultPhase 3 CLARITY-1 and CLARITY-2 of brepocitinib in non-infectious uveitis met their primary endpoint (time to treatment failure)
Roivant Sciences and Priovant Therapeutics · Source ↗
27 August 2026ApprovalFDA approves LISRAYA (brepocitinib) for adults with dermatomyositis
US, FDA · Source ↗
27 August 2026ApprovalFDA Boxed Warning on Lisraya (NDA220106)
US, FDA · FDA · Source ↗